Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 33.

Bijnsdorp, I V; Schwendener, R A; Schott, H; Fichtner, I; Smid, K; Laan, A C; Schott, S; Losekoot, N; Honeywell, R J; Peters, G J (2011). Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Investigational New Drugs, 29(2):248-257.

Schott, H; Goltz, D; Schott, T C; Jauch, C; Schwendener, R A (2011). N(4)-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). Bioorganic & Medicinal Chemistry, 19(11):3520-3526.

Schwendener, R A; Schott, H (2010). Liposome formulations of hydrophobic drugs. In: Weissig, V. Liposomes, Methods and Protocols, Vol. 1: Pharmaceutical Nanocarriers. New York, NY, USA: Humana Press, 129-138.

Schott, H; Hamprecht, K; Schott, S; Schott, T C; Schwendener, R (2009). Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. Bioorganic & Medicinal Chemistry, 17(1):303-310.

Schott, H; Schott, S; Schwendener, R (2009). Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Bioorganic & Medicinal Chemistry, 17(19):6824-6831.

Bijnsdorp, I V; Schwendener, R; Schott, H; Schott, S; Fichtner, I; Honeywell, R J; Losekoot, N; Laan, A C; Peters, G J (2008). In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine. Nucleic Acids Symposium Series (2004), (52):651.

Bijnsdorp, I V; Schwendener, R; Schott, H; Fichtner, I; Smid, K; Schott, S; Laan, A C; Peters, G J (2007). In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine. Nucleosides, Nucleotides and Nucleic Acids, 26(10-12):1619-1624.

Marty, C; Langer-Machova, Z; Sigrist, S; Schott, H; Schwendener, R; Ballmer-Hofer, K (2006). Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Letters, 235(2):298-308.

Schwendener, R; Schott, H (2005). Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Methods in Enzymology, 391:58-70.

Ludwig, P S; Schwendener, R; Schott, H (2005). Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs. European Journal of Medicinal Chemistry, 40(5):494-504.

Marty, C; Meylan, C; Schott, H; Ballmer-Hofer, K; Schwendener, R (2004). Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cellular and Molecular Life Sciences, 61(14):1785-1794.

Marty, C; Odermatt, B; Schott, H; Neri, D; Ballmer-Hofer, K; Klemenz, R; Schwendener, R (2002). Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. British Journal of Cancer, 87(1):106-112.

Schwendener, R; Friedl, K; Depenbrock, H; Schott, H; Hanauske, A R (2001). In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Investigational New Drugs, 19(3):203-210.

Cattaneo-Pangrazzi, R M; Schott, H; Wunderli-Allenspach, H; Rothen-Rutishauser, B; Guenthert, M; Schwendener, R (2000). Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 126(5):247-256.

Horber, D H; Cattaneo-Pangrazzi, R M; von Ballmoos, P; Schott, H; Ludwig, P S; Eriksson, S; Fichtner, I; Schwendener, R (2000). Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne. Journal of Cancer Research and Clinical Oncology, 126(6):311-319.

Cattaneo-Pangrazzi, R M; Schott, H; Wunderli-Allenspach, H; Derighetti, M; Schwendener, R (2000). Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Biochemical Pharmacology, 60(12):1887-96.

Cattaneo-Pangrazzi, R M; Schott, H; Schwendener, R (2000). The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate, 45(1):8-18.

Koller-Lucae, S K; Schott, H; Schwendener, R (1999). Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells. British Journal of Cancer, 80(10):1542-9.

Koller-Lucae, S K; Suter, M J; Rentsch, K M; Schott, H; Schwendener, R (1999). Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice. Drug Metabolism and Disposition, 27(3):342-350.

Schwendener, R; Peghini, P A; Ludwing, P S; Schott, H (1999). Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. Nucleosides and Nucleotides, 18(4-5):949-950.

Peghini, P A; Zahner, R; Kuster, H; Schott, H; Schwendener, R (1998). In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Antiviral Chemistry & Chemotherapy, 9(2):117-126.

Koller-Lucae, S K; Schott, H; Schwendener, R (1997). Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. Journal of Pharmacology and Experimental Therapeutics, 282(3):1572-1580.

Rentsch, K M; Schwendener, R; Schott, H; Hänseler, E (1997). Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. Journal of Pharmacy and Pharmacology, 49(11):1076-1081.

Schwendener, R; Schott, H (1996). Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Journal of Cancer Research and Clinical Oncology, 122(12):723-726.

Schwendener, R; Horber, D H; Odermatt, B; Schott, H (1996). Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine. Journal of Cancer Research and Clinical Oncology, 122(2):102-108.

Schott, H; Schwendener, R (1996). Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates. Anti-Cancer Drug Design, 11(6):451-62.

Horber, D H; von Ballmoos, P; Schott, H; Schwendener, R (1995). Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. British Journal of Cancer, 72(5):1067-1073.

Horber, D H; Schott, H; Schwendener, R (1995). Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemotherapy and Pharmacology, 36(6):483-492.

Horber, D H; Schott, H; Schwendener, R (1995). Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. British Journal of Cancer, 71(5):957-962.

Horber, D H; Ottiger, C; Schott, H; Schwendener, R (1995). Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. Journal of Pharmacy and Pharmacology, 47(4):282-288.

Rentsch, K M; Schwendener, R; Schott, H; Hänseler, E (1995). Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes. Journal of Chromatography. B, Biomedical Applications, 673(2):259-266.

Schwendener, R; Gowland, P; Horber, D H; Zahner, R; Schertler, A; Schott, H (1994). New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Research, 24(1):79-93.

Schwendener, R; Schott, H (1992). Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine. International Journal of Cancer, 51(3):466-469.

This list was generated on Sun Dec 17 00:02:49 2017 CET.